PORT-77, an oral small molecule therapy being developed to treat erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), by Gondolabio through its affiliate Portal Therapeutics, has been granted both orphan drug […] The post PORT-77 gets FDA orphan drug, fast track designations for EPP and XLP appeared first on Porphyria News.| Porphyria News – The Web's Daily Resource for Porphyria News
Adults and adolescents with erythropoietic protoporphyria (EPP) reported a significant detrimental impact of the disease on their health-related quality of life (HRQoL), as well as their social and psychosocial well-being, […] The post EPP takes major toll on patient quality of life: Study participants appeared first on Porphyria News.| Porphyria News – The Web's Daily Resource for Porphyria News
A combination of skin and liver problems in young people may be indicative of an EPP diagnosis, according to a case report.| Porphyria News
For a woman with erythropoietic protoporphyria (EPP) in China, the first symptoms did not involve the skin, as is typical, but rather the liver, drawing doctors’ attention to an unusual […] The post Rare EPP case starts with symptoms in liver, not skin, report finds appeared first on Porphyria News.| Porphyria News – The Web's Daily Resource for Porphyria News